US Stock MarketDetailed Quotes

BDX Becton Dickinson & Co

Watchlist
  • 224.800
  • -0.210-0.09%
Close Feb 14 16:00 ET
  • 224.800
  • 0.0000.00%
Post 20:01 ET
64.55BMarket Cap37.85P/E (TTM)

About Becton Dickinson & Co Company

Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, instruments, and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Company Profile

SymbolBDX
Company NameBecton Dickinson & Co
Listing DateMay 16, 1962
Issue Price25.00
Founded1897
CEOMr. Thomas E. Polen, Jr
MarketNYSE
Employees72000
Fiscal Year Ends09-30
Address1 Becton Drive
CityFranklin Lakes
ProvinceNew Jersey
CountryUnited States of America
Zip Code07417-1880
Phone1-201-847-6800

Company Executives

  • Name
  • Position
  • Salary
  • Thomas E. Polen, Jr
  • Chairman of the Board, Chief Executive Officer and President
  • 17.31M
  • Shana Carol Neal
  • Executive Vice President and Chief People Officer
  • 3.31M
  • Antoine C. Ezell
  • Executive Vice President, President, North America and Chief Marketing Officer
  • --
  • Pamela L. Spikner
  • Senior Vice President, Chief Accounting Officer and Controller
  • --
  • Christopher J. DelOrefice
  • Executive Vice President and Chief Financial Officer
  • 5.63M
  • David Shan
  • Executive Vice President and Chief Integrated Supply Chain Officer
  • --
  • Roland Goette
  • Executive Vice President and President, EMEA
  • --
  • Michael Feld
  • Executive Vice President and President, Life Sciences
  • --
  • Michelle Quinn
  • Executive Vice President and General Counsel
  • --
  • Richard E. Byrd
  • Executive Vice President and President, Interventional Segment
  • 3.27M
  • Pavan Kumar Mocherla
  • Executive Vice President and President, Greater Asia
  • --
  • Michael D. Garrison
  • Executive Vice President and President, Medical Segment
  • 3.65M
  • Jeffrey W. Henderson
  • Independent Director
  • 359.47K
  • Dr. Claire M. Fraser-Liggett,PhD
  • Independent Director
  • --
  • Christopher Ian Montague Jones
  • Independent Director
  • 359.47K
  • Timothy M. Ring
  • Independent Director
  • 344.47K
  • Dr. Joanne Waldstreicher, M.D.
  • Independent Director
  • 334.47K
  • Dr. Carrie L. Byington
  • Independent Director
  • 334.47K
  • R. Andrew Eckert
  • Independent Director
  • 364.47K
  • Catherine M. Burzik
  • Independent Director
  • 359.47K
  • Bertram L. Scott
  • Lead Independent Director
  • 374.47K
  • William M. Brown
  • Independent Director
  • 336.97K

Trending Stocks

Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Tesla's earnings caused fluctuations, what's your market outlook?
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum Show More